PDF(Pubmed)
Abstract：
Although it is known that the first case of cancer was recorded in ancient Egypt around 1600 BC, it was not until 1917 during the First World War and the development of mustard gas that chemotherapy against cancer became relevant; however, its properties were not recognised until 1946 to later be used in patients. In this sense, the use of metallopharmaceuticals in cancer therapy was extensively explored until the 1960s with the discovery of cisplatin and its anticancer activity. From that date to the present, the search for more effective, more selective metallodrugs with fewer side effects has been an area of continuous exploration. Efforts have led to considering a wide variety of metals from the periodic table, mainly from the d-block, as well as a wide variety of organic ligands, preferably with proven biological activity. In this sense, various research groups have found an ideal binder in Schiff bases, since their raw materials are easily accessible, their synthesis conditions are friendly and their denticity can be manipulated. Therefore, in this review, we have explored the anticancer and antitumor activity reported in the literature for coordination complexes of d-block metals coordinated with tridentate Schiff bases (O N O and O N N) derived from salicylaldehyde. For this work, we have used the main scientific databases CCDC® and SciFinder®.
摘要：
尽管已知第一例癌症是在公元前1600年左右的古埃及记录的，直到1917年第一次世界大战期间和芥子气的发展，化疗抗癌成为重要的;然而，它的特性直到1946年才被认可，后来被用于患者。在这个意义上,直到20世纪60年代，随着顺铂及其抗癌活性的发现，金属药物在癌症治疗中的应用被广泛探索。从那个日期到现在,寻找更有效的，更多的选择性金属药物和更少的副作用一直是一个不断探索的领域。努力导致从元素周期表中考虑各种各样的金属，主要来自D区，以及各种各样的有机配体，优选具有证明的生物活性。在这个意义上,各种研究小组已经在席夫碱中找到了理想的粘合剂，由于他们的原材料很容易获得，它们的合成条件是友好的，它们的密度可以控制。因此,在这次审查中,我们已经探索了文献中报道的d区金属与源自水杨醛的三齿席夫碱（ONO和ONN）配位的配位配合物的抗癌和抗肿瘤活性。对于这项工作，我们使用了主要的科学数据库CCDC®和SciFinder®。
